An explosion in the use of the GLP-1s like Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound has subsequently resulted in an overabundance of used needles
Protocol number: RP1-104-IGNYTE-3 A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3] Protocol number: RP2-202-NCT06581406 A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Nave Adult Patients with Metastatic Uveal Melanoma Protocol number: RPL554-NCFB-220 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Ensifentrine in Subjects with Non-Cystic Fibrosis Bronchiectasis Protocol number: RPNI Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation: A Randomized, Prospective Study Protocol number: RRTCR1-LGGAIM1 Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters AIM 1 Protocol number: RRTCR1-LGGAIM2 Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters AIM 2 Protocol number: RT234-PAH-CL202 A Phase 2b, Open-label, Single Dose Study to Evaluated the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH) Protocol number: RYZ101-301 Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1) Protocol number: S2209-NCT05561387 S2209: A PHASE III RANDOMIZED TRIAL FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS CONSIDERED FRAIL OR IN A SUBSET OF INTERMEDIATE FIT COMPARING UPFRONT THREE-DRUG INDUCTION REGIMENS FOLLOWED BY DOUBLE- OR SINGLE-AGENT MAINTENANCE
doi: 10.1007/s12630-024-02719-z
As a result, many employers find themselves in a difficult position
Does retatrutide qualify for Priority Review
